

Special Issue

New Challenges and Opportunities for Artificial Intelligence in Human Disease and Health

Message from the Guest Editors

Artificial intelligence (AI) in human disease and health is the use of machine learning models to search medical data and uncover insights to help improve health outcomes and patient experiences. With the powerful inferential capability for complex mappings, AI achieves significant performance improvements in medical data analysis. Doctors benefit from several clinical applications of the research, gaining a better understanding of human body and human disease. This research topic aims to accelerate the translation of these studies on data analysis and models into clinical applications that benefit the diagnosis and treatment of patients. This Special Issue welcomes summaries of the new challenges and opportunities of AI in human disease and health, including, but not limited to, the following applications:

- Various decision support models in the diagnosis, treatment, and prognosis of human disease;
- Few-shot learning tasks in medicine, including few-shot learning algorithms, transfer learning, and data augmentation;
- More interpretable AI model in medicine;
- Fair AI applications developed in medicine.

Guest Editors

Dr. Long Lu

Dr. Min Wang

Dr. Lianting Hu

Deadline for manuscript submissions

closed (31 January 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/138893

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).